CLX vs HRL

The Clorox Company presents as a classic value trap, characterized by a stable Piotroski F-Score of 5/9 but severely undermined by a massive valuation gap, with a current price of $98.68 far exceeding its growth-based intrinsic value of $42.77. Financial health is concerning due to critical liquidity shortages, evidenced by a Quick Ratio of 0.38 and a Current Ratio of 0.74. Negative year-over-year revenue (-0.80%) and earnings (-16.20%) growth, combined with a 0/100 technical trend, indicate a strong bearish momentum. While the 5.03% dividend is attractive, the 80.52% payout ratio is increasingly risky given the declining earnings trajectory.

HRL exhibits a stark divergence between its balance sheet health and operational performance. While the Piotroski F-Score of 7/9 indicates strong financial health and the Debt/Equity ratio (0.04) is exemplary, the company is struggling with negative YoY revenue (-2.90%) and earnings growth (-5.10%). The current price of $21.47 trades at a premium to the Graham Number ($17.0) and significantly above the growth-based intrinsic value ($6.23). Most critically, the dividend payout ratio of 130.62% is unsustainable, suggesting a high risk of a dividend cut to align with actual earnings.